Background. The surgical stress index (SSI) is a new monitoring tool for the assessment of nociception during general anaesthesia. It is calculated based on the heart beat interval and the pulse wave amplitude. Correlation of SSI with nociceptive stimuli and opioid effect-site concentrations has been demonstrated, but the influence of isolated modulation of heart rate (HR) on SSI is still unclear. The aim of this study was to evaluate the effect on SSI of atropine administration and cardiac pacing.
Recently, the surgical stress index (SSI)-also referred to as the surgical pleth index-has been proposed as a quantification of the nociception2anti-nociception balance during general anaesthesia. The SSI is a new multivariable approach which is composed 70% of the photoplethysmographic pulse wave amplitude and 30% of the normalized heart beat interval (HBI). 1 Its range is between 0 (indicating very low stress) and 100 (indicating very high stress). A detailed description of SSI can be found elsewhere. 1 The SSI has been demonstrated to correlate with surgical stress intensity and nociceptive stimuli 2 3 and also with remifentanil effect-site concentrations. 1 Therefore, it may be a helpful variable to assess nociception and to adjust the administration of analgesics during general anaesthesia and deep sedation. As the SSI is dependent on changes in HBI and the pulse wave amplitude, we studied the effect of atropine and electrical cardiac stimulation on the SSI in the absence of a painful stimulus.
Methods
After approval by the local ethics committee of the University Hospital Schleswig-Holstein, Campus Kiel, and written informed consent, 18 patients (ASA physical status III), between 68 and 81 yr, were enrolled in the study. All patients underwent elective aorto-coronary bypass graft surgery and were admitted to the intensive care unit (ICU) after operation. 
Study protocol
Study measurements started 2-3 h after arrival on the ICU. Bispectral index (BIS) (version 4.0) (BIS XP TM sensor electrodes, Aspect Medical Systems, Norwood, MA, USA, and BIS TM module, GE Healthcare) and state entropy (SE) and response entropy (RE) (M-entropy module TM , GE Healthcare) were applied immediately after arrival on ICU. Propofol administration was adjusted within the defined range to maintain a BIS value below 50. No adjustments were allowed within 30 min before start of measurements and during measurements.
During the study period, the SSI (GE Healthcare) was recorded continuously via the manufacturer's finger clip. BIS and spectral entropy were measured by the manufacturer's standard electrodes mounted side by side on the patient's temporal -frontal forehead after careful skin preparation. The electrode position was randomized to account for possible different raw EEG dependent on the brain hemisphere interrogated. Smoothing time was set to a 15 s interval for the BIS. The moving frequency-related time windows for spectral entropy calculation were 15-60 and 2-15 s for SE and RE, respectively. Sampling rate for the raw EEG was 256 Hz for BIS and 400 Hz for spectral entropy. Electrode impedances were considered acceptable if ,10 kV for BIS and ,7.5 kV for spectral entropy.
First, the influence of pacemaker-modulated HR changes on SSI was analysed. The pacemaker-if in use-was switched off and SSI, BIS, and SE and RE values were allowed to stabilize for 5 min until start of measurements. During measurement, SSI, BIS, RE, SE, MAP, and HR were recorded every 1 min manually. These variables were derived from a time period of 10 s (median of five values) at the end of every minute to minimize artifacts. Five minutes after start of measurements without stimulation (interval I), the pacemaker was switched on (80 beats min 21 , AAI mode) for 5 min (interval II), then HR was increased to 100 beats min 21 (AAI mode) for another 5 min (interval III). Afterwards, the pacemaker was switched off again for a 5 min period (interval IV) before it was switched on (100 beats min 21 ) for 15 min (interval V -VII).
Twenty-five minutes after the start of measurement, the SSI finger clip was first disconnected from the patient's finger for 1 min and after reconnection on the patient's index finger, SSI was allowed to recalibrate for 5 min (interval VI) followed by a final 5 min measuring interval (interval VII) (intervals were also illustrated in Fig. 1A ). Secondly, we investigated the influence of atropine administration on SSI. After a 5 min calibration period, measurements were started. SSI, BIS, RE, SE, MAP, and HR were recorded manually every 1 min for 5 min, then atropine (10 mg kg 21 i. v.) was administered followed by a study period of 10 min. Then, SSI was disconnected from the patient's finger for 1 min and recalibrated for 5 min as described above followed by a final study period of 5 min.
Statistical analysis
Data were analysed using commercially available statistics software (GraphPad Prism 5, GraphPad Software Inc., San Diego, CA, USA). Variables before and after electrical or pharmacological intervention were analysed with the Wilcoxon signed-rank test and the Mann -Whitney U-test, as appropriate. A P-value of ,0.05 was considered statistically significant. The effect of pacemaker stimulation on SSI was analysed by comparisons of defined time intervals (I vs III, V vs VII, and IV vs VII) (Fig. 1) . Corrections for multiple testing were performed. Data are presented as median [inter-quartile, IQR (range)] or mean (SD) as appropriate.
Results
Eighteen patients were enrolled in the study. No patient had to be excluded. Patient characteristics are presented in Table 1 . (Fig. 2) .
Influence of cardiac pacemaker stimulation

Discussion
In our prospective observational study, isolated stimulation of HR with a cardiac pacemaker or with atropine in anaesthetized patients resulted in a considerable increase in SSI, whereas MAP and EEG-derived variables SE, RE, and BIS remained unchanged. During pacing, recalibration of SSI induced a significant decrease in SSI, whereas after atropine administration, recalibration had no effect on SSI values.
The SSI was first described by Huiku and colleagues 1 who investigated the index in patients who underwent general anaesthesia with propofol and remifentanil for gynaecological or breast surgery. In comparison with other variables analysed, SSI showed best correlation to actual concentration of remifentanil and intensity of painful stimulation. Therefore, SSI was introduced as a tool for the monitoring of the nociception-anti-nociception balance. Several studies have investigated SSI during different anaesthetic regimes and patients. 2 -5 Ahonen and colleagues 2 studied 30 women who underwent gynaecological laparoscopy under desflurane/nitrous oxide/fentanyl anaesthesia. The patients received additionally either remifentanil or esmolol during surgery. SSI values in the esmolol group were higher than in the remifentanil group. Interestingly, during the whole study period, HR, systolic arterial pressure, and entropy (SE and RE) were not different between the groups. This indicated a remifentanil-effect on SSI that is independent from isolated HR modulation. However, the published studies so far investigated only young and healthy patients (mostly ASA physical status I) and-with the exception of Ahonen and colleagues 2 -did not analyse the influence of vasoactive or HR modulating drugs or electric cardiac stimulation on SSI. However, anaesthesia in older patients often requires the administration of vasoactive or HR modulating drugs and in occasional cases the use of a cardiac pacemaker. Therefore, it is important to evaluate and to know possible limitations of this index to avoid misinterpretation of the data obtained.
As might be expected from the SSS algorithm, our results indicate a very strong dependence of SSI on modulation of HR during a largely constant nociception-anti-nociception balance. Recalibration of the device had a differential effect. Recalibration following atropine had no effect on SSI values. In contrast, recalibration during pacemaker stimulation resulted in SSI values that were significantly lower than before at identical HR but significantly higher than at baseline HR. The increase and also the baseline of HR and SSI were comparable in both study groups which otherwise may have affected our findings.
A potential mechanism responsible for this differential effect may be the different HR variability (HRV) which is preserved in the atropine group but nullified in the pacemaker group. Several variables affecting HRV have been identified: depth of anaesthesia and analgesia, nociceptive stimuli, HR, direct cardiovascular drug effects, and individual co-morbidities (e.g. coronary heart disease), but the interaction between these factors is still unclear.
6 -8 Some of these variables seemed to be comparable between the study groups. However, systemic effects of atropine which may affect HR and HRV alone or potentially have a direct influence on the nociception-anti-nociception balance cannot be excluded. Finally, the published algorithm of SSI calculation 1 does not include any 'learning effect' which may lead to a different analysis of a sudden tachycardia dependent on a low or high baseline HR. An HR increase accompanied by a preserved or nullified HRV and may help to explain the observed differential effects in our study. As a result, SSI monitoring in patients with pacemakers should at least be accompanied by repeated recalibration. On the other hand, SSI data in patients receiving HR modulating drugs like atropine should be interpreted cautiously. Recalibration of the device under these circumstances seems not to be a promising strategy.
Several limitations of the present study have to be mentioned. We enrolled only anaesthetized ASA III ICU patients after aorto-coronary bypass graft surgery into our study. All of them had a cardiac pacemaker and were suffering from coronary heart disease, most of them from general atherosclerosis and other co-morbidities. This may affect their reaction to stimulation. Although we adjusted the propofol infusion rate according to a defined BIS target and demonstrated that BIS and spectral entropy values were stable during measurements, we could not guarantee pharmacological steady-state conditions during the study period. Moreover, the individual baseline stress level or pain of every patient could not be quantified but may have influenced the results.
In conclusion, we demonstrated that an increase in HR induced by a cardiac pacemaker or by atropine resulted in a noticeable increase in SSI even without any additional modulation of the nociception -anti-nociception balance. EEG-derived parameters SE, RE, and BIS and also MAP remained constant, indicating deep hypnosis. Therefore, SSI data in patients receiving drugs with pronounced effects on Effect of heart rate on SSI HR like atropine and in patients with cardiac pacemakers should be interpreted with caution.
